article thumbnail

Sebi’s Shift towards the T+0 Settlement System

IP and Legal Filings

Introduction Recently on 28 th March 2024, India’s stock market-initiated T+0 settlement system which is world’s fastest stock settlement system. The same day transaction settlement i.e. T+0 is launched for a select few cash segment stocks. This settlement is particularly aimed at accelerating the trade settlement cycle.

article thumbnail

Marketing Co. Can't Escape Verbal Settlement Deal

IP Law 360

A Colorado federal judge has found that two email marketing companies verbally agreed to settle their trade secrets dispute, siding with a magistrate judge who had presided over the settlement negotiations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nestle Strikes Deal Ending Gray-Market Drinks Trademark Row

IP Law 360

and two food distributors have asked a Texas federal judge to permanently dismiss their trademark infringement fight accusing the distributors of illegally selling so-called gray-market versions of Nescafe Clasico and Abuelita products, saying parties recently reached a settlement agreement. Nestle USA Inc.

article thumbnail

Client Marketing May Be 'Fair Game' In Atty Fight, Judge Says

IP Law 360

Courts might not have the authority to order an attorney to refrain from marketing to a competitor's clients, an "exceptionally skeptical" Connecticut federal judge observed Friday as he considered a dispute arising from a settlement between two former law partners.

article thumbnail

Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J

LexBlog IP

announced that they reached a settlement and license agreement with Johnson & Johnson regarding AVT04, Alvotech’s proposed biosimilar to STELARA (ustekinumab) in the United States. The post Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J appeared first on Big Molecule Watch.

article thumbnail

Alvotech Announces More Settlements and Expected Launch Dates Regarding Biosimilar to STELARA (ustekinumab), AVT04

LexBlog IP

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech has commercial partners for AVT04 in each of the aforementioned markets. Per the settlement agreement, AVT04 can be marketed in the U.S.,

article thumbnail

Formycon/Fresenius Kabi and Samsung Bioepis Settlements with J&J and Janssen Biotech regarding Ustekinumab

LexBlog IP

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.